Hello bar1080, That's an easy answer. The contest is for a one week period, Nov 20 to Nov 24 and I don't expect MRKR to do anything in the next week. I used a stock that I honestly think is a scam (SHOT) but knowing how penny stock players think and how it has been moving for the last 2 weeks, I figured it was the best "one week" bet I could make.
But back to MRKR, Let's leave aside bio technologies like RNAI and MRNA and CRISPR (which are all genetically engineered and have all had severe side effect problems including patient deaths) and just compare CAR-T to MRKR's Mulit-TAA, it is hard not to see the advantage of Multi-TAA (Tumor Associated Antigens).
CAR-T (chimeric antigen receptor -T cell therapy) is ALSO genetically engineered.
Has had many problems with Cytokine release syndrome (BAD).
Has killed patients (WORSE than BAD).
Only targets one antigen.
Costs much more and takes much longer to produce.
Multi-TAA is NOT genetically engineered.
Has had NO problems with Cytokine release syndrome or patient deaths.
Targets Multi antigens for each specific cancer indication.
Induces Epitope spreading (the body creates other antigens to target the cancer naturally besides those that were introduced).
Costs much less and much quicker to produce.
Has had success so far in Phase 1 and Phase 2 trials.
MRKR, IF IF IF everything goes according to plan, will pay off big in the second half of 2024 and in 2025.
By the summer of 2024, we should have a decent amount of trial data on AML and Lymphoma.
Also working on Panceatic (a ways off and a much tougher cancer to crack).
As we discussed on the other IHUB board, when you buy them when they are small and hold them, an up 10,000% is not out of the question.
VRTX, SGEN,EXEL,ALNY, ARWR, PCYC (bought by AbbVie), all went from small to many Billions in market cap for me.
But as you never really know when good news will come out, you just have to buy and hold, but for MRKR, it should be an end of 2024/2025 big payoff.
Another much closer payoff is IOVA who is working on TIL technology. TIL - tumor infiltrating lymphocyte therapy.
We are waiting for final data and FDA approval in Feb. 2024.
BIG payoff IF IF IF. Gilead might just buy them out.
Speaking of Gilead, MRKR has a sister company, Allovir, ALVR (same founders) that Gilead own a giant chunk of.
I know that you are a bond and dividend guy, but check all 3 of them out, you may want to take a small flyer position on 1 or 2 or all 3 of them.
Good Luck.
Bullish
